Enalapril for severe congestive heart failure. A double-blind study.
The effects of the new, orally administered converting-enzyme inhibitor, enalapril (MK-421), were studied in 12 ambulatory patients with severe cardiac failure who were also receiving digoxin and diuretic agents. The study was double-blind, parallel, placebo-controlled and randomized. The clinical characteristics and pretreatment exercise performance were similar in the two groups of patients. All vasodilator drugs had been withdrawn two weeks before the start of the trial. At 12 weeks, the patients receiving enalapril showed a significant improvement in the functional class of the disease, exercise time (P less than 0.01), and maximum workload achieved, and experienced relief of symptoms. Blood pressure fell in patients receiving active treatment suggesting a reduction of afterload. Left ventricular ejection fraction was unchanged in enalapril-treated patients, but fell in patients on placebo (P less than 0.001). Enalapril was well tolerated without apparent adverse effects. It was effective when used with digoxin and diuretic agents in the treatment of severe cardiac failure, and its efficacy was maintained throughout 12 weeks of therapy.
D000284:Administration, Oral; D000368:Aged; D002986:Clinical Trials as Topic; D004151:Dipeptides / Q000627:therapeutic use*; D004311:Double-Blind Method; D004656:Enalapril; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005080:Exercise Test; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors
D004151:Dipeptides; D004791:Enzyme Inhibitors; D004656:Enalapril